84 related articles for article (PubMed ID: 28039709)
21. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
[TBL] [Abstract][Full Text] [Related]
22. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
[TBL] [Abstract][Full Text] [Related]
23. [Screening for predictive biomarkers of bevacizumab treatment in gastric cancer subcutaneous xenografts].
Zhang Q; Xu J; Ye J; Yuan Y; Chen J; Peng J; He Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Feb; 18(2):177-80. PubMed ID: 25656129
[TBL] [Abstract][Full Text] [Related]
24. Peptide micelle-mediated delivery of tissue-specific suicide gene and combined therapy with avastin in a glioblastoma model.
Oh B; Han J; Choi E; Tan X; Lee M
J Pharm Sci; 2015 Apr; 104(4):1461-9. PubMed ID: 25631673
[TBL] [Abstract][Full Text] [Related]
25. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
[TBL] [Abstract][Full Text] [Related]
26. [Inhibitive effect of celecoxib combined with tegafur gimeracil oteracil potassium on the growth of xenograft tumor of gastric cancer in nude mice].
Meng C; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 May; 29(5):458-61. PubMed ID: 23643260
[TBL] [Abstract][Full Text] [Related]
27. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
29. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
Gao ZQ; Han BH; Sha HF; Shi ZY; Yang XH; Feng JX
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr; 33(4):284-8. PubMed ID: 20646461
[TBL] [Abstract][Full Text] [Related]
30. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.
Gong Y; Ren J; Liu K; Tang LM
World J Gastroenterol; 2015 Mar; 21(10):2949-58. PubMed ID: 25780292
[TBL] [Abstract][Full Text] [Related]
31. The role of additional chemotherapy with oral UFT in intravenous combination chemotherapy with cisplatin and 5-fluorouracil for human gastric cancer xenograft lines of well- and poorly- differentiated adenocarcinomas transplanted in nude mice.
Tseng CC; Nio Y; Tsubono M; Kawabata K; Masai Y; Hayashi H; Fukumoto M; Tobe T
Anticancer Res; 1992; 12(4):1295-9. PubMed ID: 1503424
[TBL] [Abstract][Full Text] [Related]
32. [Effects of bevacizumab and cisplatin on human lung adenocarcinoma A549/DDP xenografts in nude mice].
Dai M; Luo RC; Zheng DY; Lü CW; Ding XM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1402-5. PubMed ID: 17884788
[TBL] [Abstract][Full Text] [Related]
33. Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
Kristian A; Revheim ME; Qu H; Mælandsmo GM; Engebråten O; Seierstad T; Malinen E
Acta Oncol; 2013 Oct; 52(7):1566-72. PubMed ID: 23984812
[TBL] [Abstract][Full Text] [Related]
34. [Antitumor and antimetastatic effect of antimicrobial peptide conjugated with tumor homing peptide TMTP1 on the transplanted prostate cancer and gastric cancer in nude mice].
Ma XY; Li S; Luo DF; Liu RH; Lu YP; Wang SX; Ma D; Xi L
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):737-41. PubMed ID: 24378093
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy.
Ou G; Itasaka S; Zeng L; Shibuya K; Yi J; Harada H; Hiraoka M
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):463-7. PubMed ID: 19735869
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model.
Chen T; Yuan SJ; Wang J; Hu W
World J Gastroenterol; 2015 Sep; 21(35):10126-36. PubMed ID: 26401077
[TBL] [Abstract][Full Text] [Related]
39. [Effects of combined therapy of LY294002 and SN50 on nude mice model with gastric cancer].
Sun JL; Zhu BS; Gong W; Zhang P; Yu LY; Zhao K; Xing CG
Zhonghua Wei Chang Wai Ke Za Zhi; 2011 May; 14(5):364-7. PubMed ID: 21614693
[TBL] [Abstract][Full Text] [Related]
40. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]